

PERSONAL INFORMATION

Laura Masuelli

University of Rome "Sapienza", Department of Experimental Medicine

CURRENT POSITION


Associate Professor of General Pathology (ssd MED/04)

Medical School, University of Rome "Sapienza"

ADDITIONAL ACADEMIC POSITIONS

Vicedirettore Residency Program in Clinical Pathology,

Medical School, University of Rome "Sapienza"



RESEARCH FIELD (MAX 1000 characters space included)

In the last few years, Prof. Masuelli has been involved in the morpho-molecular and immunological characterization of microvesicles and exosomes as novel biomarkers in in vitro experimental preclinical models and in patients' liquid biopsies (cancer patients and cerebrovascular patients). Moreover, she is involved in the multiomic transitions especially for the characterization of circulating miRNAs or proteins as novel potential biomarkers in cancer. She has a long experience on the analysis of the in vitro and in vivo biological effects of drugs for target therapy, used alone or in combination, employing preclinical models for anti-cancer therapy. These drugs include inhibitors of growth factor receptors and cytoplasmic signaling molecules. Prof. Masuelli has a long experience on the analysis of the in vitro and in vivo biological effects of nutraceuticals, used alone or in combination, employing preclinical models for anti-cancer treatment and prevention, and for cardiomyopathies. Moreover, she has a long experience on the study of cancer immunology including the development of anti-cancer vaccines using preclinical models. Prof. Laura Masuelli is employed as Dirigente Medico I livello at the Azienda Ospedaliera Universitaria Policlinico Umberto I where she is involved in ultrastructural diagnosis of human diseases (including kidney pathology, lysosomal storage diseases, pulmonary pathologies, amyloidosis) using transmission electron microscopy on human biopsies. Moreover, she performs ultrastructural characterization of primary cell cultures derived from patients affected by neurological disorders or lysosomal storage diseases. In the last few years, Prof. Masuelli has been involved in the characterization of nanosystems for the delivery of nucleic acids, drugs and nutraceuticals for anti-cancer therapy. Finally, she has been also involved in the characterization of different signal transduction pathways altered during carcinogenesis, including growth factor receptors, transducers, small G proteins.

WORK EXPERIENCE

- 2018- to date **Associate Professor of General Pathology (ssd MED/04)**
School of Medicine, University of Rome "Sapienza".
- 2009-to date **Dirigente Medico I livello, UOC Molecular Oncology EOC09 (from 2018 UOSD SSDD04 Molecular Oncology)**
Azienda ospedaliera universitaria Policlinico Umberto I, Rome
Ultrastructural diagnoses of human diseases
- 2017 **FAS (delibera n. 000688 del 21/06/2017, Conferimento Prot. N. 002596 del 10/07/)**
Azienda ospedaliera universitaria Policlinico Umberto I, Rome
- 2015-2018 **Associate Professor of Technical Sciences of Laboratory Medicine (ssd MED/46)**
School of Medicine, University of Rome "Sapienza".
- 2005-2009 **Dirigente Medico I livello, UOC Molecular Oncology BDB09**
Azienda ospedaliera universitaria Policlinico Umberto I, Rome
Ultrastructural diagnoses of human diseases
- 1998-2005 **Dirigente Medico I livello, S.S. CHM03 Oncology**
Azienda ospedaliera universitaria Policlinico Umberto I, Rome
Care activity in the Oncology Department
Ultrastructural diagnoses of human diseases
- 1998-2015 **Researcher of General Pathology (ssd MED/04)**
School of Medicine, University of Rome "Sapienza".

EDUCATION AND TRAINING

- 2017 **ASN qualification as FULL PROFESSOR ssd MED/04 (exp. 01/08/2028)**
- 1997 **Residency in Medical Oncology (70/70 cum Laude)**
University of Rome "Sapienza".
- 1995 **Ph.D in Experimental Medicine**
University of Rome "Sapienza".
- Jul-Sep 1996 **Visiting scientist**
Department of Pathology, Uniformed Services University of the Health Science Bethesda, Maryland, USA
- 1992-1996 **Fogarty Fellowship**
Experimental Oncology Section, Laboratory of Tumor Immunology and Biology, NCI, NIH, Bethesda, Maryland, USA (Director Dr. J. Schlom)
- 1989 **M.D. Degree in Medicine (110/110 cum Laude)**
University of Rome "Sapienza"

ACADEMIC APPOINTMENTS

- 2023 **Member of the Strategic Plan Working Group**
Member of the Instrumentation Commission
Member of the Commission for the Organization of new instrumental resources
Department of Experimental Medicine, University of Rome "Sapienza"
- 2022- to date **Vicedirettore Residency Program in Clinical Pathology and Biochemistry**
University of Rome "Sapienza"
- 2001- to date **Coordinator of integrated course Physiopathological bases of the diseases**
CdL A Physiotherapy University of Rome "Sapienza"
- 2014- to date **Board member PhD in Molecular Medicine**
University of Rome "Sapienza"
- 2022- to date **Coordinator of integrated course Advanced technologies in laboratory diagnostics**
University of Rome "Sapienza" CdL F Tecnico di Laboratorio Biomedico, Rieti
- 2009-2019 **Membro Comitato Ordinatore Scuola di Specializzazione in Patologia Clinica e Biochimica Clinica**
University of Rome "Sapienza"
- 2003-2005 **Board member PhD in Biotechnology,**
University of L'Aquila

ADDITIONAL INFORMATION

Publications and main indexes

Total number of publications in peer-review journals: **125** (pubmed/scopus) H-Index: **37** (scopus), Total citations: **4806** (19/07/2023) Cit. medie: **38.448**
Total IF (2022): **707.605** Total IF(anno pubbl.): **619.638**
IF medio (2022): **5.94** IF medio (anno pubbl.): **5.207**

Google Scholar Page: <https://scholar.google.com/citations?user=EORC30laaaaJ&hl=it>
Scopus ID: 6603345787. ORCID: <https://orcid.org/0000-0001-8174-8034>

**1998-2001
CLINICAL TRIAL**

Participation as an external collaborator in the **SUC-LIS95 clinical trial** "Phase III controlled clinical study against placebo on the therapeutic efficacy and tolerability of the medicinal product SUC-LIS95 based on sucralfate gel in patients with vascular ulcers" approved by the University Ethics Committee of Rome Sapienza (protocol # SUCTOP/0497). This study resulted in two publications and two congress oral presentations

Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action.

Masuelli L, Tumino G, Turriziani M, Modesti A, Bei R. Recent Pat Inflamm Allergy Drug Discov. 2010 Jan;4(1):25-36. doi: 10.2174/187221310789895649. PMID: 19832693

Topical treatment of chronic venous ulcers with sucralfate: a placebo controlled randomized study.

Tumino G, **Masuelli L**, Bei R, Simonelli L, Santoro A, Francipane S. Int J Mol Med. 2008 Jul;22(1):17-23. PMID: 18575771 **Clinical Trial**.

6° AGE National Congress (Parma 2009) Simposio: Il ruolo del sucralfato nella cicatrizzazione delle ulcere

Laura Masuelli: Utilizzo del sucralfato nelle ulcere

7° AGE National Congress (Palermo 2010) Sesta sessione: Il ruolo del sucralfato nella cicatrizzazione delle ulcere

Laura Masuelli: Utilizzo del sucralfato nelle ulcere

Main funded projects**Principal Investigator or
Co-Principal Investigator**

PRIN 2022 Responsabile di unità di ricerca: Novel mediators, predictive biomarkers and therapeutic targets for breast cancer metastatic disease (Approvato in attesa attribuzione risorse)

PNRR 2022: PNC D³ 4 HEALTH Co-Pi Spoke 3 Linea Tematica 2 “Digital Twins construction: Omics and liquid biopsy biomarkers” (1.900.000,00 euro)

Ateneo Progetti Medi Sapienza 2022: Studio degli effetti antitumorali della combinazione di farmaci a bersaglio molecolare nel mesotelioma maligno (RM12218166C5057A) (10.000,00 euro)

Ateneo Progetti Medi Sapienza 2021: Combinazione di farmaci multi- e uni-target come potenziale terapia mirata nel mesotelioma maligno (RM12117A7F986146) (10.000,00 euro)

Ateneo Progetti Medi Sapienza 2020: Effetti antitumorali in vitro ed in vivo del trattamento con l'inibitore del proteasoma Bortezomib nel mesotelioma maligno (RM120172A840E501) (33.787,00 euro)

Ateneo Progetti Medi Sapienza 2019: Mesotelioma maligno: effetto antitumorale in vitro del trattamento con gli inibitori Afatinib e GANT-61 (RM11916B74788236) (10.000,00 euro)

Ateneo Progetti Piccoli Sapienza 2018: Effetto antitumorale del trattamento con il composto BH3-mimetico AT-101 nel mesotelioma maligno (RP1181641D1AD88C) (3.000,00 euro)

Ateneo Progetti Piccoli Sapienza 2017: Effetto antitumorale del trattamento con l'enantiomero negativo del gossypol (AT-101) nella terapia dell'osteosarcoma. (RP11715C7C73A80E) (3.500,00 euro)

Ateneo Progetti Piccoli Sapienza 2016: Effetto antitumorale del trattamento con gossypol nella terapia e nella prevenzione dei tumori testa-collo (RP116154C82216ED) (4.000,00 euro)

Ricerche universitarie Sapienza 2012: Effetto antitumorale del trattamento combinato con polifenoli nella terapia e nella prevenzione dei tumori testa-collo (C26A12AXEH) (6.000,00 euro)

Ateneo Federato Sapienza 2008/2009: Effetti dei polifenoli e dei tiosulfonati sull'espressione di molecole di adesione nei tumori cervico-facciali (C26F09EEYB-C26F08SMPP) (5.000,00 euro)

PRIN 2007 Responsabile di unità di ricerca “DIALOGO TRA I FIBROBLASTI GENGIVALI E LE CELLULE INFIAMMATORIE DURANTE L'ATTIVAZIONE DELL'IMMUNITÀ INNATA: STUDIO DEL RIMODELLAMENTO DEI COMPONENTI DELLA MATRICE EXTRACELLULARE, DELLA PRODUZIONE DELLE PROTEINE DELLO SHOCK TERMICO E DELL'ATTIVITÀ CHEMIOTATTICA”, nell'ambito del progetto nazionale dal titolo: “RIMODELLAMENTO DEI TESSUTI MOLLI PERI-IMPLANTARI IN PAZIENTI SOTTOPOSTI AD IMPIANTI DENTALI: IMPLICAZIONI PER LA RIUSCITA DEL TRATTAMENTO IMPLANTARE E NUOVE PROSPETTIVE BIOLOGICHE”, coordinatore nazionale Prof. Adriano Piattelli. (49.000,00 euro)

Ateneo Federato Sapienza 2006/2007: Rimodellamento dei dischi intercalari in corso di cardiomiopatia ipertrofica e dilatativa (3.000,00 euro)

Ateneo Federato Sapienza 2004/2005: Interazione tra i recettori della famiglia ErbB e il complesso caderina-catenine nei tumori cervico-facciali (C26F058528- C26F048242) (3.000,00 euro)

PRIN 2004 Responsabile di unità di ricerca "VACCINAZIONE INTRATUMORALE CON POXVIRUS ESPRIMENTI HER-2/neu E MOLECOLE COSTIMOLATORIE NELLA PREVENZIONE E NELLA TERAPIA DI TUMORI MAMMARI IPERESPRIMENTI HER-2/neu", nell'ambito del progetto nazionale dal titolo: "IL RECETTORE HER2/ERBB2 NELLA PROGRESSIONE, PREVENZIONE E TERAPIA DEI TUMORI", coordinatore nazionale Prof. Guido Forni (35.800,00 euro)

PRIN 2002 Responsabile di unità di ricerca "RISPOSTA IMMUNITARIA ED ATTIVITA' ANTITUMORALE INDOTTA DA VACCINAZIONE CON RECETTORI ErbB OMOLOGHI IN TOPI TRANSGENICI PER HER2/neu", nell'ambito del progetto nazionale dal titolo: "LE BASI SPERIMENTALI PER LA COSTRUZIONE DI VACCINI PER PREVENIRE L'INSORGENZA DI CARCINOMI HER-2/NEU (ERBB-2) POSITIVI", coordinatore nazionale Prof. Guido Forni. (44.500,00 euro)

Investigator

PNRR 2022 PE10 ONFOODS - Modelli per un'alimentazione sostenibile spoke 6 linea tematica 1 MASSA CRITICA (400.000,00 euro)

Ateneo Federato Sapienza 2011/2012: Ruolo dell'ormone tiroideo nella regolazione metabolica della fibronectina tessutale e plasmatica (C26A11TREA) (8.000,00 euro)

Ricerche Universitarie Sapienza 2010: Attività regolatoria esercitata dal microambiente extracellulare su proliferazione e apoptosi di adenocarcinomi corticosurrenalici in vitro (C26A10MKAW) (10.000,00 euro)

Publications

(IF2022/anno pubbl)

SJR ranking (quartiles)

[1. Tumor Microenvironment Remodeling in Gastrointestinal Cancer: Role of miRNAs as Biomarkers of Tumor Invasion.](#)

Lucarini V, Nardozi D, Angiolini V, Benvenuto M, Focaccetti C, Carrano R, Besharat ZM, Bei R, **Masuelli L**. *Biomedicines*. 2023 Jun 19;11(6):1761. doi: 10.3390/biomedicines11061761 PMID: 37371856 (IF 4.757) (SJR **Q1**) (cit.0)

[2. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients.](#)

Besharat ZM, Trocchianesi S, Verrienti A, Ciampi R, Cantara S, Romei C, Sabato C, Noviello TMR, Po A, Citarella A, Caruso FP, Panariello I, Gianni F, Carpino G, Gaudio E, Chiacchiarini M, **Masuelli L**, Sponziello M, Pecce V, Ramone T, Maino F, Dotta F, Ceccarelli M, Pezzullo L, Durante C, Castagna MG, Elisei R, Ferretti E. *J Endocrinol Invest*. 2023 Jun 7. doi: 10.1007/s40618-023-02115-2. PMID: 37286863 (IF 5.4) (SJR **Q2**) (cit.0)

[3. Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing.](#)

Vulpis E, Loconte L, Cassone C, Antonangeli F, Caracciolo G, Masuelli L, Fazio F, Petrucci MT, Fionda C, Soriani A, Cerboni C, Cippitelli M, Santoni A, Zingoni A. *Int J Mol Sci*. 2023 May 30;24(11):9467. doi: 10.3390/ijms24119467. PMID: 37298418 (IF 5.6) (SJR **Q1**) (cit.0)

[4. Hyaluronan-estradiol nanogels as potential drug carriers to target ER+ breast cancer cell line.](#)

Paoletti L, Zoratto N, Benvenuto M, Nardozi D, Angiolini V, Mancini P, **Masuelli L**, Bei R, Frajese GV, Matricardi P, Nalli M, Di Meo C. *Carbohydr Polym*. 2023 Aug 15;314:120900. doi: 10.1016/j.carbpol.2023.120900. Epub 2023 Apr 13. PMID: 37173041 (IF 11.2) (SJR **Q1**) (cit.0)

[5. Antitumoral effects of Bortezomib in malignant mesothelioma: evidence of mild endoplasmic reticulum stress in vitro and activation of T cell response in vivo.](#)

Benvenuto M, Angiolini V, Focaccetti C, Nardozi D, Palumbo C, Carrano R, Rufini A, Bei R, Miele MT, Mancini P, Barillari G, Cirone M, Ferretti E, Tundo GR, Mutti L, **Masuelli L**, Bei R. *Biol Direct*. 2023 Apr 17;18(1):17. doi: 10.1186/s13062-023-00374-w. PMID: 37069690 (IF 5.5) (SJR **Q1**) (cit.0) **CO-LAST Author**

[6. Novel Therapeutic Targets for Tumor Microenvironment in Cancer.](#)

Bei R. and **Masuelli L**. *Int. J. Mol. Sci*. 2023, 24, 7240. <https://doi.org/10.3390/ijms24087240> PMID: 37108403 (IF 5.6) (SJR **Q1**) (cit.0)

[7. Doxorubicin-Mediated miR-433 Expression on Exosomes Promotes Bystander Senescence in Multiple Myeloma Cells in a DDR-Independent Manner.](#)

Vulpis E, Cuollo L, Borrelli C, Antonangeli F, **Masuelli L**, Cippitelli M, Fionda C, Caracciolo G, Petrucci MT, Santoni A, Zingoni A, Soriani A. *Int J Mol Sci*. 2023 Apr 6;24(7):6862. doi: 10.3390/ijms24076862. PMID: 37047835 (IF 5.6) (SJR **Q1**) (cit.0)

[8. Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasite *Anisakis pegreffii* \(Nematoda: Anisakidae\).](#)

Palomba M, Ruggetti A, Mignogna G, Castrignanò T, Rahimi H, **Masuelli L**, Napoletano C, Pinna V, Giorgi A, Santoro M, Schininà ME, Maras B, Mattiucci S. *Front Cell Infect Microbiol*. 2023 Mar 15;13:1079991. doi: 10.3389/fcimb.2023.1079991. PMID: 37009516 (IF 5.7) (SJR **Q1**) (cit.0)

[9. Hedgehog-GLI and Notch Pathways Sustain Chemoresistance and Invasiveness in Colorectal Cancer and Their Inhibition Restores Chemotherapy Efficacy.](#)

Citarella A, Catanzaro G, Besharat ZM, Trocchianesi S, Barbagallo F, Gosti G, Leonetti M, Di Fiore A, Coppola L, Autilio TM, Spinello Z, Vacca A, De Smaele E, Venneri MA, Ferretti E, **Masuelli L**, Po A. *Cancers (Basel)*. 2023 Feb 25;15(5):1471. doi: 10.3390/cancers15051471. PMID: 36900263 (IF 5.2) (SJR **Q1**) (cit.2) **CO-LAST Author**

[10. Recent findings on the impact of ErbB receptors status on prognosis and therapy of head and neck squamous cell carcinoma](#)

Palumbo C, Benvenuto M, Focaccetti C, Albonici L, Cifaldi L, Rufini A, Nardozi D, Angiolini V, Bei A, **Masuelli L**, Bei R. *Front Med (Lausanne)*. 2023 Feb 2;10:1066021. doi:

10.3389/fmed.2023.1066021. (IF 3.9) (SJR Q1) (cit.0)

11. [Different outcome of targeting ERN1/IRE1 alpha and EIF2AK3/PERK in NSG mice engrafted with primary effusion lymphoma.](#)

Arena A, Romeo MA, Focaccetti C, Anastasiadou E, Trivedi P, Cifaldi L, Gilardini Montani MS, Benedetti R, Santarelli R, Gonnella R, Benvenuto M, Marchese C, **Masuelli L**, Bei R, Cirone M. *Br J Haematol.* 2023 Feb 12. doi: 10.1111/bjh.18688. Online ahead of print. (IF 6.5) (SJR Q1) (cit.0)

12. [Mechanistic Insights into the Superior DNA Delivery Efficiency of Multicomponent Lipid Nanoparticles: An In Vitro and In Vivo Study.](#)

Quagliarini E, Wang J, Renzi S, Cui L, Digiacomo L, Ferri G, Pesce L, De Lorenzi V, Matteoli G, Amenitsch H, **Masuelli L**, Bei R, Pozzi D, Amici A, Cardarelli F, Marchini C, Caracciolo G. *ACS Appl Mater Interfaces.* 2022 Dec 28;14(51):56666-56677. doi: 10.1021/acsami.2c20019. Epub 2022 Dec 16. PMID: 36524967 (IF 9.5) (SJR Q1) (cit.2)

13. [A novel microRNA signature for the detection of melanoma by liquid biopsy.](#)

Sabato C, Noviello TMR, Covre A, Coral S, Caruso FP, Besharat ZM, Splendiani E, **Masuelli L**, Battistelli C, Vacca A, Catanzaro G, Po A, Anichini A, Maio M, Ceccarelli M, Di Giacomo AM, Ferretti E. *J Transl Med.* 2022 Oct 15;20(1):469. doi: 10.1186/s12967-022-03668-1. PMID: 36243798 (IF 7.4) (SJR Q1) (cit.5)

14. [Efficient Delivery of DNA Using Lipid Nanoparticles.](#)

Cui L, Renzi S, Quagliarini E, Digiacomo L, Amenitsch H, **Masuelli L**, Bei R, Ferri G, Cardarelli F, Wang J, Amici A, Pozzi D, Marchini C, Caracciolo G. *Pharmaceutics.* 2022 Aug 15;14(8):1698. doi: 10.3390/pharmaceutics14081698. PMID: 36015328 (IF 5.4) (SJR Q1) (cit.5)

15. [Syntaxin-1a and SNAP-25 expression level is increased in the blood samples of ischemic stroke patients.](#)

Cappelletti P, Filareti M, **Masuelli L**, Bei R, Hassanzadeh K, Corbo M, Feligioni M. *Sci Rep.* 2022 Aug 25;12(1):14483. doi: 10.1038/s41598-022-18719-2. PMID: 36008522 (IF 4.6) (SJR Q1) (cit.0)

16. [Combined treatment with inhibitors of ErbB Receptors and Hh signaling pathways is more effective than single treatment in reducing the growth of malignant mesothelioma both in vitro and in vivo.](#)

Bei R, Benvenuto M, Focaccetti C, Fazi S, Moretti M, Nardozi D, Angiolini V, Ciuffa S, Cifaldi L, Carrano R, Palumbo C, Miele MT, Bei R, Barillari G, Manzari V, De Smaele E, Modesti A, **Masuelli L**. *J Transl Med.* 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9. PMID: 35752861 (IF 7.4) (SJR Q1) (cit.2)

17. [Phenotypic and genetic spectrum of ATP6V1A encephalopathy: a disorder of lysosomal homeostasis.](#)

Guerrini R, Mei D, Kerti-Szigeti K, Pepe S, Koenig MK, Von Allmen G, Cho MT, McDonald K, Baker J, Bhambhani V, Powis Z, Rodan L, Nabbout R, Barcia G, Rosenfeld JA, Bacino CA, Mignot C, Power LH, Harris CJ, Marjanovic D, Møller RS, Hammer TB; DDD Study; Keski Filppula R, Vieira P, Hildebrandt C, Sacharow S; Undiagnosed Diseases Network; Maragliano L, Benfenati F, Lachlan K, Benneche A, Petit F, de Sainte Agathe JM, Hallinan B, Si Y, Wentzensen IM, Zou F, Narayanan V, Matsumoto N, Boncristiano A, la Marca G, Kato M, Anderson K, Barba C, Sturiale L, Garozzo D, Bei R; ATP6V1A collaborators; **Masuelli L**, Conti V, Novarino G, Fassio A. *Brain.* 2022 Aug 27;145(8):2687-2703. doi: 10.1093/brain/awac145. PMID: 35675510 (IF 14.5) (SJR Q1) (cit.3)

18. [Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients.](#)

Pantano F, Zalfa F, Iuliani M, Simonetti S, Manca P, Napolitano A, Tiberi S, Russano M, Citarella F, Foderaro S, Vulpis E, Zingoni A, **Masuelli L**, Bei R, Ribelli G, Del Re M, Danesi R, Vincenzi B, Perrone G, Tonini G, Santini D. *Cancers (Basel).* 2022 May 14;14(10):2435. doi: 10.3390/cancers14102435. PMID: 35626040 (IF 5.2) (SJR Q1) (cit.7)

19. [Opsonin-Deficient Nucleoproteic Corona Endows UnPEGylated Liposomes with Stealth](#)

Properties *In Vivo*.

Giulimondi F, Vulpis E, Digiaco L, Giuli MV, Mancusi A, Capriotti AL, Laganà A, Cerrato A, Zenezini Chiozzi R, Nicoletti C, Amenitsch H, Cardarelli F, **Masuelli L**, Bei R, Screpanti I, Pozzi D, Zingoni A, Checquolo S, Caracciolo G. *ACS Nano*. 2022 Feb 22;16(2):2088-2100. doi: 10.1021/acsnano.1c07687. Epub 2022 Jan 18. PMID: 35040637 (IF 17.1) (SJR Q1) (cit.14)

20. Impact on NK cell functions of acute versus chronic exposure to extracellular vesicle-associated MICA: Dual role in cancer immunosurveillance.

Vulpis E, Loconte L, Peri A, Molfetta R, Caracciolo G, **Masuelli L**, Tomaipitnca L, Peruzzi G, Petillo S, Petrucci MT, Fazio F, Simonelli L, Fionda C, Soriani A, Cerboni C, Cippitelli M, Paolini R, Bernardini G, Palmieri G, Santoni A, Zingoni A. *J Extracell Vesicles*. 2022 Jan;11(1):e12176. doi: 10.1002/jev2.12176. PMID: 34973063 (IF 16) (SJR Q1) (cit.14)

21. Clinical variability at the mild end of BRAT1-related spectrum: Evidence from two families with genotype-phenotype discordance.

Nuovo S, Baglioni V, De Mori R, Tardivo S, Caputi C, Ginevrino M, Micalizzi A, **Masuelli L**, Federici G, Casella A, Lorefice E, Anello D, Tolve M, Farini D, Bertini E, Zanni G, Travaglini L, Vasco G, Sette C, Carducci C, Valente EM, Leuzzi V. *Hum Mutat*. 2022 Jan;43(1):67-73. doi: 10.1002/humu.24293. Epub 2021 Nov 15. PMID: 34747546 (IF 3.9) (SJR Q1) (cit.7)

22. De novo DHDDS variants cause a neurodevelopmental and neurodegenerative disorder with myoclonus.

Galosi S, Edani BH, Martinelli S, Hansikova H, Eklund EA, Caputi C, **Masuelli L**, Corsten-Janssen N, Srour M, Oegema R, Bosch DGM, Ellis CA, Amlie-Wolf L, Accogli A, Atallah I, Averdunk L, Barañano KW, Bei R, Bagnasco I, Brusco A, Demarest S, Alaix AS, Di Bonaventura C, Distelmaier F, Elmslie F, Gan-Or Z, Good JM, Gripp K, Kamsteeg EJ, Macnamara E, Marcelis C, Mercier N, Peeden J, Pizzi S, Pannone L, Shinawi M, Toro C, Verbeek NE, Venkateswaran S, Wheeler PG, Zdrzilova L, Zhang R, Zorzi G, Guerrini R, Sessa WC, Lefeber DJ, Tartaglia M, Hamdan FF, Grabińska KA, Leuzzi V. *Brain*. 2022 Mar 29;145(1):208-223. doi: 10.1093/brain/awab299. PMID: 34382076 (IF 14.5) (SJR Q1) (cit.7)

23. Stillbirth and fetal capillary infection by SARS-CoV-2.

di Gioia C, Zullo F, Bruno Vecchio RC, Pajno C, Perrone G, Galoppi P, Pecorini F, Di Mascio D, Carletti R, Prezioso C, Pietropaolo V, **Masuelli L**, Bei R, Ciallella C, Della Rocca C, Giacotti A, Brunelli R. *Am J Obstet Gynecol MFM*. 2022 Jan;4(1):100523. doi: 10.1016/j.ajogmf.2021.100523. Epub 2021 Oct 24. PMID: 34700024 (IF 6.3/ 8.679) (SJR Q1) (cit.13)

24. New Insights into Curcumin- and Resveratrol-Mediated Anti-Cancer Effects.

Arena A, Romeo MA, Benedetti R, **Masuelli L**, Bei R, Gilardini Montani MS, Cirone M. *Pharmaceuticals (Basel)*. 2021 Oct 22;14(11):1068. doi: 10.3390/ph14111068. PMID: 34832850 (IF 4.6/ 5.215) (SJR Q1) (cit.20)

25. Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells.

Benvenuto M, Ciuffa S, Focaccetti C, Sbardella D, Fazi S, Scimeca M, Tundo GR, Barillari G, Segni M, Bonanno E, Manzari V, Modesti A, **Masuelli L**, Coletta M, Bei R. *Sci Rep*. 2021 Sep 24;11(1):19051. doi: 10.1038/s41598-021-98450-6. PMID: 34561494 (IF 4.6/ 4.996) (SJR Q1) (cit.12)

26. Polyphenols affect the humoral response in cancer, infectious and allergic diseases and autoimmunity by modulating the activity of TH1 and TH2 cells.

Benvenuto M, Focaccetti C, Ciuffa S, Fazi S, Bei A, Miele MT, Albonici L, Cifaldi L, **Masuelli L**, Bei R. *Curr Opin Pharmacol*. 2021 Oct;60:315-330. doi: 10.1016/j.coph.2021.08.005. Epub 2021 Sep 11. PMID: 34520942 Review. (IF 4/ 4.798) (SJR Q1) (cit.8) **O-LAST Author**

27. Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery.

Quagliarini E, Renzi S, Digiaco L, Giulimondi F, Sartori B, Amenitsch H, Tassinari V, **Masuelli**

- L, Bei R, Cui L, Wang J, Amici A, Marchini C, Pozzi D, Caracciolo G. *Pharmaceutics*. 2021 Aug 19;13(8):1292. doi: 10.3390/pharmaceutics13081292.PMID: 34452253 (IF 5.4/ 6.525) (SJR Q1) (cit.18)
28. [Neurodegeneration in Niemann-Pick Type C Disease: An Updated Review on Pharmacological and Non-Pharmacological Approaches to Counteract Brain and Cognitive Impairment.](#) Cariati I, **Masuelli L**, Bei R, Tancredi V, Frank C, D'Arcangelo G. *Int J Mol Sci*. 2021 Jun 20;22(12):6600. doi: 10.3390/ijms22126600.PMID: 34202978. Review. (IF 5.6/ 6.208) (SJR Q1) (cit.9)
29. [Guidelines for the use and interpretation of assays for monitoring autophagy \(4th edition\)¹.](#) Klionsky DJ, et al. *Autophagy*. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8.PMID: 33634751 (IF 13.3/ 13.391) (SJR Q1) (cit.955)
30. [PGE2 Released by Pancreatic Cancer Cells Undergoing ER Stress Transfers the Stress to DCs Impairing Their Immune Function.](#) Gilardini Montani MS, Benedetti R, Piconese S, Pulcinelli FM, Timperio AM, Romeo MA, **Masuelli L**, Mattei M, Bei R, D'Orazi G, Cirone M. *Mol Cancer Ther*. 2021 May;20(5):934-945. doi: 10.1158/1535-7163.MCT-20-0699. Epub 2021 Feb 25.PMID: 33632872 (IF 5.7/ 6.009) (SJR Q1) (cit.9)
31. [Targeting the tumor immune microenvironment with "nutraceuticals": From bench to clinical trials.](#) **Masuelli L**, Benvenuto M, Focaccetti C, Ciuffa S, Fazi S, Bei A, Miele MT, Piredda L, Manzari V, Modesti A, Bei R. *Pharmacol Ther*. 2021 Mar;219:107700. doi: 10.1016/j.pharmthera.2020.107700. Epub 2020 Oct 9.PMID: 33045254 Review. (IF 13.5/ 13.4) (SJR Q1) (cit.11)
32. [Tumor antigens heterogeneity and immune response-targeting neoantigens in breast cancer.](#) Benvenuto M, Focaccetti C, Izzi V, **Masuelli L**, Modesti A, Bei R. *Semin Cancer Biol*. 2021 Jul;72:65-75. doi: 10.1016/j.semcancer.2019.10.023. Epub 2019 Nov 4.PMID: 31698088 Review. (IF 14.2/ 17.012) (SJR Q1) (cit.21)
33. [Human Fibroblasts In Vitro Exposed to 2.45 GHz Continuous and Pulsed Wave Signals: Evaluation of Biological Effects with a Multimethodological Approach.](#) Regalbutto E, Anselmo A, De Sanctis S, Franchini V, Lista F, Benvenuto M, Bei R, **Masuelli L**, D'Inzeo G, Paffi A, Trodella E, Sgura A. *Int J Mol Sci*. 2020 Sep 25;21(19):7069. doi: 10.3390/ijms21197069.PMID: 32992895 (IF 5.6/ 5.924) (SJR Q1) (cit.7)
34. [Polyphenol-Mediated Autophagy in Cancer: Evidence of In Vitro and In Vivo Studies.](#) Benvenuto M, Albonici L, Focaccetti C, Ciuffa S, Fazi S, Cifaldi L, Miele MT, De Maio F, Tresoldi I, Manzari V, Modesti A, **Masuelli L**, Bei R. *Int J Mol Sci*. 2020 Sep 10;21(18):6635. doi: 10.3390/ijms21186635.PMID: 32927836 Review. (IF 5.6/ 5.924) (SJR Q1) (cit.18) **CO-LAST Author**
35. [Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine \(rV-neuT\) in Mice with Transplanted Salivary Gland Carcinoma Cells.](#) Focaccetti C, Benvenuto M, Ciuffa S, Fazi S, Scimeca M, Nardi A, Miele MT, Battisti A, Bonanno E, Modesti A, **Masuelli L**, Bei R. *Nutrients*. 2020 May 14;12(5):1417. doi: 10.3390/nu12051417.PMID: 32423101 (IF 5.9/5.719) (SJR Q1) (cit.10) **CO-LAST Author**
36. [Different continuous training modalities result in distinctive effects on muscle structure, plasticity and function.](#) Pallone G, Palmieri M, Cariati I, Bei R, **Masuelli L**, D'Arcangelo G, Tancredi V. *Biomed Rep*. 2020 May;12(5):267-275. doi: 10.3892/br.2020.1283. Epub 2020 Feb 28.PMID: 32257190 (SJR Q1) (cit.7)
37. [Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-κB Transcription Factor.](#)

Mekhloufi A, Kosta A, Stabile H, Molfetta R, Zingoni A, Soriani A, Cippitelli M, Paolini R, Gismondi A, Ricciardi MR, Petrucci MT, **Masuelli L**, Caracciolo G, Palchetti S, Santoni A, Fionda C. *Cancers (Basel)*. 2020 Feb 13;12(2):440. doi: 10.3390/cancers12020440.PMID: 32069911 (IF 5.2/ 6.639) (SJR Q1) (cit.17)

38. [In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101](#). **Masuelli L**, Benvenuto M, Izzi V, Zago E, Mattera R, Cerbelli B, Potenza V, Fazi S, Ciuffa S, Tresoldi I, Lucarelli E, Modesti A, Bei R. *Invest New Drugs*. 2020 Jun;38(3):675-689. doi: 10.1007/s10637-019-00827-y. Epub 2019 Jul 2. PMID: 31264066 (IF3.4/ 3.85) (SJR Q1) (cit.9)

39. [Immune complexes exposed on mast cell-derived nanovesicles amplify allergic inflammation](#). Molfetta R, Lecce M, Quatrini L, Caracciolo G, Digiaco L, **Masuelli L**, Milito ND, Vulpis E, Zingoni A, Galandrini R, Santoni A, Paolini R. *Allergy*. 2020 May;75(5):1260-1263. doi: 10.1111/all.14103. Epub 2019 Nov 28. PMID: 31713871. (IF 12.4/ 13.146) (SJR Q1) (cit.13)

40. [Effects of a natural multi-component compound formulation on the growth, morphology and extracellular matrix production of human adult dermal fibroblasts](#). Benvenuto M, Mattera R, Miele MT, Giganti MG, Tresoldi I, Albonici L, Manzari V, Modesti A, **Masuelli L**, Bei R. *Exp Ther Med*. 2019 Oct;18(4):2639-2647. doi: 10.3892/etm.2019.7872. Epub 2019 Aug 8. PMID: 31572512 (IF 1.785/ 2.7) (SJR Q2) **CO-LAST Author**

41. [Broadening phenotype of adenylosuccinate lyase deficiency: A novel clinical pattern resembling neuronal ceroid lipofuscinosis](#). Mastrangelo M, Alfonsi C, Screpanti I, **Masuelli L**, Tavazzi B, Mei D, Giannotti F, Guerrini R, Leuzzi V. *Mol Genet Metab Rep*. 2019 Aug 21;21:100502. doi: 10.1016/j.ymgmr.2019.100502. eCollection 2019 Dec. PMID: 31467849 (IF 3.8/ 4.17) (SJR Q2) (cit.2)

42. [Interplay of protein corona and immune cells controls blood residency of liposomes](#). Giulimondi F, Digiaco L, Pozzi D, Palchetti S, Vulpis E, Capriotti AL, Chiozzi RZ, Laganà A, Amenitsch H, **Masuelli L**, Peruzzi G, Mahmoudi M, Screpanti I, Zingoni A, Caracciolo G. *Nat Commun*. 2019 Aug 15;10(1):3686. doi: 10.1038/s41467-019-11642-7. PMID: 31417080 (IF 16.6/ 12.121) (SJR Q1) (cit.127)

43. [Impact of HHV-6A and HHV-6B lytic infection on autophagy and endoplasmic reticulum stress](#). Romeo MA, **Masuelli L**, Gaeta A, Nazzari C, Granato M, Gilardini Montani MS, Faggioni A, Cirone M. *J Gen Virol*. 2019 Jan;100(1):89-98. doi: 10.1099/jgv.0.001176. Epub 2018 Nov 14. PMID: 30427305 (IF 3.8/ 3.376) (SJR Q2) (cit.20)

44. [Effect of the BH3 Mimetic Polyphenol \(-\)-Gossypol \(AT-101\) on the in vitro and in vivo Growth of Malignant Mesothelioma](#). Benvenuto M, Mattera R, Sticca JI, Rossi P, Cipriani C, Giganti MG, Volpi A, Modesti A, **Masuelli L**, Bei R. *Front Pharmacol*. 2018 Nov 6;9:1269. doi: 10.3389/fphar.2018.01269. eCollection 2018. PMID: 30459622 (IF 5.6/ 3.845) (SJR Q1) (cit.21) **CO-LAST Author**

45. [Cancer stem cells from peritumoral tissue of glioblastoma multiforme: the possible missing link between tumor development and progression](#). Angelucci C, D'Alessio A, Lama G, Binda E, Mangiola A, Vescovi AL, Proietti G, **Masuelli L**, Bei R, Fazi B, Ciafrè SA, Sica G. *Oncotarget*. 2018 Jun 15;9(46):28116-28130. doi: 10.18632/oncotarget.25565. eCollection 2018 Jun 15. PMID: 29963265 (IF 2016 5.168) (SJR Q2) (cit.24)

46. [Genotoxic Effects in Human Fibroblasts Exposed to Microwave Radiation](#). Franchini V, Regalbutto E, De Amicis A, De Sanctis S, Di Cristofaro S, Coluzzi E, Marinaccio J, Sgura A, Ceccuzzi S, Doria A, Gallerano GP, Giovenale E, Ravera GL, Bei R, Benvenuto M, Modesti A, **Masuelli L**, Lista F. *Health Phys*. 2018 Jul;115(1):126-139. doi: 10.1097/HP.0000000000000871. PMID: 29787439 (IF 2.2/ 0.993) (SJR Q2) (cit.12)

47. [Drug-Induced Senescent Multiple Myeloma Cells Elicit NK Cell Proliferation by Direct or](#)

[Exosome-Mediated IL15 Trans-Presentation.](#)

Borrelli C, Ricci B, Vulpis E, Fionda C, Ricciardi MR, Petrucci MT, **Masuelli L**, Peri A, Cippitelli M, Zingoni A, Santoni A, Soriani A. *Cancer Immunol Res.* 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604. Epub 2018 Apr 24. PMID: 29691234 (IF 10.1/ 8.619) (SJR Q1) (cit.55)

48. [Study of the effects of 0.15 terahertz radiation on genome integrity of adult fibroblasts.](#)

Franchini V, De Sanctis S, Marinaccio J, De Amicis A, Coluzzi E, Di Cristofaro S, Lista F, Regalbuto E, Doria A, Giovenale E, Gallerano GP, Bei R, Benvenuto M, **Masuelli L**, Udroui I, Sgura A. *Environ Mol Mutagen.* 2018 Jul;59(6):476-487. doi: 10.1002/em.22192. Epub 2018 Mar 30. PMID: 29602275 (IF 2.8/ 2.528) (SJR Q2) (cit.26)

49. [Biological Effects of 25 to 150 GHz Radiation After In Vitro Exposure of Human Fibroblasts: a Comparison of Experimental Results](#)

Franchini V, Ceccuzzi S, Doria A, Gallerano GP, Giovenale E, Ravera GL, De Amicis A, De Sanctis S, Di Cristofaro S, Regalbuto E, Coluzzi E, Marinaccio J, Sgura A, Bei R, Benvenuto M, Modesti A, **Masuelli L**, Lista F. *Journal of Infrared, Millimeter, and Terahertz Waves* Volume 39, Issue 9, Pages 899 - 9111 September 2018 (IF 2.9/ 1.762) (SJR Q2) (cit.2)

50. [Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells *in vitro* and *in vivo* in nude mice while counteracts it in immune competent mice.](#)

Masuelli L, Granato M, Benvenuto M, Mattera R, Bernardini R, Mattei M, d'Amati G, D'Orazi G, Faggioni A, Bei R, Cirone M. *Oncoimmunology.* 2017 Jul 31;6(11):e1356151. doi: 10.1080/2162402X.2017.1356151. eCollection 2017. PMID: 29147611 (IF 7.2/ 5.503) (SJR Q1) (cit.35)

51. [In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma.](#)

Masuelli L, Benvenuto M, Mattera R, Di Stefano E, Zago E, Taffera G, Tresoldi I, Giganti MG, Frajese GV, Berardi G, Modesti A, Bei R. *Front Pharmacol.* 2017 Jun 19;8:373. doi: 10.3389/fphar.2017.00373. eCollection 2017. PMID: 28674496 (IF 5.6/ 3.831) (SJR Q1) (cit.52)

52. [Effects of Polyphenols on Oxidative Stress-Mediated Injury in Cardiomyocytes.](#)

Mattera R, Benvenuto M, Giganti MG, Tresoldi I, Pluchinotta FR, Bergante S, Tettamanti G, **Masuelli L**, Manzari V, Modesti A, Bei R. *Nutrients.* 2017 May 20;9(5):523. doi: 10.3390/nu9050523. PMID: 28531112 Review. (IF 5.9/ 4.196) (SJR Q1) (cit.76)

53. [Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.](#)

Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, **Masuelli L**, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A. *Oncoimmunology.* 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017. PMID: 28405503 (IF 7.2/ 5.503) (SJR Q1) (cit.91)

54. [The crossroads between cancer immunity and autoimmunity: antibodies to self antigens.](#)

Benvenuto M, Mattera R, **Masuelli L**, Tresoldi I, Giganti MG, Frajese GV, Manzari V, Modesti A, Bei R. *Front Biosci (Landmark Ed).* 2017 Mar 1;22(8):1289-1329. doi: 10.2741/4545. PMID: 28199204 Review. (IF 3.1/ 2.349) (SJR Q2) (cit. 16)

55. [Curcumin blocks autophagy and activates apoptosis of malignant mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant mesothelioma cell line.](#)

Masuelli L, Benvenuto M, Di Stefano E, Mattera R, Fantini M, De Feudis G, De Smaele E, Tresoldi I, Giganti MG, Modesti A, Bei R. *Oncotarget.* 2017 May 23;8(21):34405-34422. doi: 10.18632/oncotarget.14907. PMID: 28159921 (IF 2016 5.168) (SJR Q2) (cit.63)

56. [\(±\)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice.](#)

Benvenuto M, Mattera R, **Masuelli L**, Taffera G, Andracchio O, Tresoldi I, Lido P, Giganti MG, Godos J, Modesti A, Bei R. *Int J Food Sci Nutr*. 2017 May;68(3):298-312. doi: 10.1080/09637486.2016.1236077. Epub 2016 Sep 27. PMID: 27670669 (IF 3.9/ 2.317) (SJR Q1) (cit.16)

57. [Physical exercise modulates the level of serum MMP-2 and MMP-9 in patients with breast cancer.](#)

Giganti MG, Tresoldi I, Sorge R, Melchiorri G, Triossi T, **Masuelli L**, Lido P, Albonici L, Foti C, Modesti A, Bei R. *Oncol Lett*. 2016 Sep;12(3):2119-2126. doi: 10.3892/ol.2016.4887. Epub 2016 Jul 20. PMID: 27602150 (IF 2.9/ 1.39) (SJR Q3) (cit.18)

58. [A novel LAMP2 mutation associated with severe cardiac hypertrophy and microvascular remodeling in a female with Danon disease: a case report and literature review.](#)

Bottillo I, Giordano C, Cerbelli B, D'Angelantonio D, Lipari M, Polidori T, Majore S, Bertini E, D'Amico A, Giannarelli D, De Bernardo C, **Masuelli L**, Musumeci F, Avella A, Re F, Zachara E, d'Amati G, Grammatico P. *Cardiovasc Pathol*. 2016 Sep-Oct;25(5):423-31. doi: 10.1016/j.carpath.2016.07.005. Epub 2016 Jul 25. PMID: 27497751 (IF 3.7/ 2.359) (SJR Q1) (cit.29)

59. [Potassium increases the antitumor effects of ascorbic acid in breast cancer cell lines *in vitro*.](#)

Frajese GV, Benvenuto M, Fantini M, Ambrosin E, Sacchetti P, **Masuelli L**, Giganti MG, Modesti A, Bei R. *Oncol Lett*. 2016 Jun;11(6):4224-4234. doi: 10.3892/ol.2016.4506. Epub 2016 Apr 27. PMID: 27313770 (IF 2.9/ 1.39) (SJR Q3) (cit.23)

60. [The Potential Protective Effects of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of Mesothelium.](#)

Benvenuto M, Mattera R, Taffera G, Giganti MG, Lido P, **Masuelli L**, Modesti A, Bei R. *Nutrients*. 2016 May 9;8(5):275. doi: 10.3390/nu8050275. PMID: 27171110 Review. (IF 5.9/ 3.55) (SJR Q1) (cit.22)

61. [In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO \(GDC-0449\) or GLI \(GANT-61\) inhibitors.](#)

Benvenuto M, **Masuelli L**, De Smaele E, Fantini M, Mattera R, Cucchi D, Bonanno E, Di Stefano E, Frajese GV, Orlandi A, Screpanti I, Gulino A, Modesti A, Bei R. *Oncotarget*. 2016 Feb 23;7(8):9250-70. doi: 10.18632/oncotarget.7062. PMID: 26843616 **CO-FIRST Author** (IF 0/ 5.168) (SJR Q2) (cit.92)

62. [Violacein, an indole-derived purple-colored natural pigment produced by *Janthinobacterium lividum*, inhibits the growth of head and neck carcinoma cell lines both *in vitro* and *in vivo*.](#)

Masuelli L, Pantanella F, La Regina G, Benvenuto M, Fantini M, Mattera R, Di Stefano E, Mattei M, Silvestri R, Schippa S, Manzari V, Modesti A, Bei R. *Tumour Biol*. 2016 Mar;37(3):3705-17. doi: 10.1007/s13277-015-4207-3. Epub 2015 Oct 13. PMID: 26462840 (IF 0/ 3.65) (SJR Q2) (cit.44)

63. [Biological effects of *in vitro* THz radiation exposure in human foetal fibroblasts.](#)

De Amicis A, Sanctis SD, Cristofaro SD, Franchini V, Lista F, Regalbutto E, Giovenale E, Gallerano GP, Nenzi P, Bei R, Fantini M, Benvenuto M, **Masuelli L**, Coluzzi E, Cicia C, Sgura A. *Mutat Res Genet Toxicol Environ Mutagen*. 2015 Nov;793:150-60. doi: 10.1016/j.mrgentox.2015.06.003. Epub 2015 Jun 9. PMID: 26520385 (IF 1.9/ 2.254) (SJR Q3) (cit.53)

64. [Targeting estrogen receptor \$\beta\$ as preventive therapeutic strategy for Leber's hereditary optic neuropathy.](#)

Pisano A, Preziuso C, Iommarini L, Perli E, Grazioli P, Campese AF, Maresca A, Montopoli M, **Masuelli L**, Sadun AA, d'Amati G, Carelli V, Ghelli A, Giordano C. *Hum Mol Genet*. 2015 Dec 15;24(24):6921-31. doi: 10.1093/hmg/ddv396. Epub 2015 Sep 26. PMID: 26410888 (IF 3.5/ 5.985) (SJR Q1) (cit.60)

65. [In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment.](#)

- Fantini M, Benvenuto M, **Masuelli L**, Frajese GV, Tresoldi I, Modesti A, Bei R. *Int J Mol Sci*. 2015 Apr 24;16(5):9236-82. doi: 10.3390/ijms16059236.PMID: 25918934 Review. (IF 5.6/ 3.257) (SJR **Q1**) (cit.247)
66. [Natural humoral immune response to ribosomal P0 protein in colorectal cancer patients.](#)
Benvenuto M, Sileri P, Rossi P, **Masuelli L**, Fantini M, Nanni M, Franceschilli L, Sconocchia G, Lanzilli G, Arriga R, Faggioni G, Lista F, Orlandi A, Manzari V, Gaspari AL, Modesti A, Bei R. *J Transl Med*. 2015 Mar 28;13:101. doi: 10.1186/s12967-015-0455-7.PMID: 25889931 (IF 7.4/ 3.694) (SJR **Q1**) (cit.18)
67. [Resveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomas.](#)
Masuelli L, Di Stefano E, Fantini M, Mattera R, Benvenuto M, Marzocchella L, Sacchetti P, Focaccetti C, Bernardini R, Tresoldi I, Izzi V, Mattei M, Frajese GV, Lista F, Modesti A, Bei R. *Oncotarget*. 2014 Nov 15;5(21):10745-62. doi: 10.18632/oncotarget.2534.PMID: 25296980 (IF 6.359) (SJR **Q2**) (cit.89)
68. [Fracture healing: from basic science to role of nutrition.](#)
Giganti MG, Tresoldi I, **Masuelli L**, Modesti A, Grosso G, Liuni FM, Celi M, Rao C, Gasbarra E, Bei R, Tarantino U. *Front Biosci (Landmark Ed)*. 2014 Jun 1;19(7):1162-75. doi: 10.2741/4273.PMID: 24896342 Review. (IF 3.1/3.523) (SJR **Q2**) (cit.25)
69. [Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.](#)
Masuelli L, Fantini M, Benvenuto M, Sacchetti P, Giganti MG, Tresoldi I, Lido P, Lista F, Cavallo F, Nanni P, Schlom J, Modesti A, Bei R. *J Transl Med*. 2014 May 10;12:122. doi: 10.1186/1479-5876-12-122.PMID: 24886178 (IF 7.4/ 3.694) (SJR **Q1**) (cit. 16)
70. [Poxvirus-based vaccines for cancer immunotherapy: new insights from combined cytokines/co-stimulatory molecules delivery and "uncommon" strains.](#)
Izzi V, Buler M, **Masuelli L**, Giganti MG, Modesti A, Bei R. *Anticancer Agents Med Chem*. 2014 Feb;14(2):183-9. doi: 10.2174/18715206113136660376.PMID: 24237219 Review. (IF 2.8/ 2.469) (SJR **Q3**) (cit.12)
71. [Tendon's ultrastructure.](#)
Tresoldi I, Oliva F, Benvenuto M, Fantini M, **Masuelli L**, Bei R, Modesti A. *Muscles Ligaments Tendons J*. 2013 May 21;3(1):2-6. doi: 10.11138/mltj/2013.3.1.002. Print 2013 Jan.PMID: 23885339 (SJR **Q3**) (cit.32)
72. [Inhibition of ErbB receptors, Hedgehog and NF-kappaB signaling by polyphenols in cancer.](#)
Benvenuto M, Fantini M, **Masuelli L**, De Smaele E, Zazzeroni F, Tresoldi I, Calabrese G, Galvano F, Modesti A, Bei R. *Front Biosci (Landmark Ed)*. 2013 Jun 1;18(4):1290-310. doi: 10.2741/4180.PMID: 23747884 Review. (IF 3.1/ 4.249) (SJR **Q2**) (cit.25)
73. [Effects of vitamin C on health: a review of evidence.](#)
Grosso G, Bei R, Mistretta A, Marventano S, Calabrese G, **Masuelli L**, Giganti MG, Modesti A, Galvano F, Gazzolo D. *Front Biosci (Landmark Ed)*. 2013 Jun 1;18(3):1017-29. doi: 10.2741/4160.PMID: 23747864 Review. (IF 3.1/ 4.249) (SJR **Q2**) (cit.165)
74. [Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.](#)
Masuelli L, Benvenuto M, Fantini M, Marzocchella L, Sacchetti P, Di Stefano E, Tresoldi I, Izzi V, Bernardini R, Palumbo C, Mattei M, Lista F, Galvano F, Modesti A, Bei R. *J Biol Regul Homeost Agents*. 2013 Jan-Mar;27(1):105-19.PMID: 23489691 (IF 3.2/ 2.406) (SJR **Q3**) (cit.65)
75. [Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients.](#)
Ingrosso G, Fantini M, Nardi A, Benvenuto M, Sacchetti P, **Masuelli L**, Ponti E, Frajese GV, Lista F,

- Schillaci O, Santoni R, Modesti A, Bei R. *Oncol Rep.* 2013 Mar;29(3):1167-74. doi: 10.3892/or.2012.2197. Epub 2012 Dec 18. PMID: 23254686 (IF 4.2/ 2.191) (SJR Q2) (cit. 11)
76. [West Nile alternative open reading frame \(N-NS4B/WARF4\) is produced in infected West Nile Virus \(WNV\) cells and induces humoral response in WNV infected individuals.](#)
Faggioni G, Pomponi A, De Santis R, **Masuelli L**, Ciammaruconi A, Monaco F, Di Gennaro A, Marzocchella L, Sambri V, Lelli R, Rezza G, Bei R, Lista F. *Viro J.* 2012 Nov 22;9:283. doi: 10.1186/1743-422X-9-283. PMID: 23173701 (IF 4.8/ 2.092) (SJR Q1) (cit. 14)
77. [The effects of dietary flavonoids on the regulation of redox inflammatory networks.](#)
Izzi V, **Masuelli L**, Tresoldi I, Sacchetti P, Modesti A, Galvano F, Bei R. *Front Biosci (Landmark Ed).* 2012 Jun 1;17(7):2396-418. doi: 10.2741/4061. PMID: 22652788 Review. (IF 3.1/3.286) (SJR Q2) (cit.94)
78. [Carcinoembryonic antigen \(CEA\)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials.](#)
Turriziani M, Fantini M, Benvenuto M, Izzi V, **Masuelli L**, Sacchetti P, Modesti A, Bei R. *Recent Pat Anticancer Drug Discov.* 2012 Sep;7(3):265-96. doi: 10.2174/157489212801820020. PMID: 22630596 Review. (IF 2.8/ 2.7) (SJR Q3) (cit.39)
79. [Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies.](#)
Izzi V, **Masuelli L**, Tresoldi I, Foti C, Modesti A, Bei R. *Cancer Lett.* 2012 Sep 1;322(1):18-34. doi: 10.1016/j.canlet.2012.02.034. Epub 2012 Mar 3. PMID: 22394996 Review. (IF 9.7/ 4.258) (SJR Q1) (cit.45)
80. [Caveolin-1 overexpression is associated with simultaneous abnormal expression of the E-cadherin/ \$\alpha\$ - \$\beta\$ catenins complex and multiple ErbB receptors and with lymph nodes metastasis in head and neck squamous cell carcinomas.](#)
Masuelli L, Budillon A, Marzocchella L, Mrozek MA, Vitolo D, Di Gennaro E, Losito S, Sale P, Longo F, Ionna F, Lista F, Muraro R, Modesti A, Bei R. *J Cell Physiol.* 2012 Sep;227(9):3344-53. doi: 10.1002/jcp.24034. PMID: 22213373 (IF 5.6/ 4.218) (SJR Q1) (cit.42)
81. [Resveratrol and diallyl disulfide enhance curcumin-induced sarcoma cell apoptosis.](#)
Masuelli L, Marzocchella L, Focaccetti C, Tresoldi I, Palumbo C, Izzi V, Benvenuto M, Fantini M, Lista F, Tarantino U, Modesti A, Galvano F, Bei R. *Front Biosci (Landmark Ed).* 2012 Jan 1;17(2):498-508. doi: 10.2741/3940. PMID: 22201757 (IF 3.1/ 3.286) (SJR Q2) (cit.41)
82. [Impaired expression and function of cancer-related enzymes by anthocyanins: An update](#)
Bei R, Palumbo C, **Masuelli L**, Turriziani M, Frajese GV, Volti G, Malaguarnera M, Galvano F. *Current Enzyme Inhibition* Volume 8, Issue 1, Pages 2 - 21 May 2012 (SJR Q4) (cit.5)
83. [Dietary flavonoids: molecular mechanisms of action as anti-inflammatory agents.](#)
Marzocchella L, Fantini M, Benvenuto M, **Masuelli L**, Tresoldi I, Modesti A, Bei R. *Recent Pat Inflamm Allergy Drug Discov.* 2011 Sep;5(3):200-20. doi: 10.2174/187221311797264937. PMID: 21827399 Review. (SJR Q1) (cit. 140)
84. [Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells.](#)
Cerquetti L, Sampaoli C, Amendola D, Bucci B, **Masuelli L**, Marchese R, Misiti S, De Venanzi A, Poggi M, Toscano V, Stigliano A. *Exp Cell Res.* 2011 Jun 10;317(10):1397-410. doi: 10.1016/j.yexcr.2011.02.014. Epub 2011 Mar 3. PMID: 21376716 (IF 3.7/ 3.58) (SJR Q2) (cit.41)
85. [Effects of omega-3 polyunsaturated fatty acids on cardiac myocyte protection.](#)
Bei R, Frigiola A, **Masuelli L**, Marzocchella L, Tresoldi I, Modesti A, Galvano F. *Front Biosci (Landmark Ed).* 2011 Jan 1;16(5):1833-43. doi: 10.2741/3825. PMID: 21196268 Review. (IF 3.1/ 3.52) (SJR Q2) (cit.8)

86. [Apigenin induces apoptosis and impairs head and neck carcinomas EGFR/ErbB2 signaling.](#) **Masuelli L**, Marzocchella L, Quaranta A, Palumbo C, Pompa G, Izzi V, Canini A, Modesti A, Galvano F, Bei R. *Front Biosci (Landmark Ed)*. 2011 Jan 1;16(3):1060-8. doi: 10.2741/3735.PMID: 21196218 (IF 3.1/ 3.52) (SJR **Q2**) (cit.57)
87. [Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice.](#) Marzocchella L, Sini V, Buonomo O, Orlandi A, **Masuelli L**, Bonanno E, Lista F, Turriziani M, Manzari V, Roselli M, Modesti A, Bei R. *Cancer Sci*. 2011 Mar;102(3):509-15. doi: 10.1111/j.1349-7006.2010.01814.x. Epub 2010 Dec 22.PMID: 21175994 (IF 5.7/ 3.325) (SJR **Q1**) (cit. 16)
88. [Patients with peri-implantitis, unlike those with a healthy periimplant microenvironment, display antibodies to more than one heat shock protein \(HSP 27, HSP 65 and HSP 90\) linear epitope](#) **Masuelli L**, Pompa G, Fabrizi M, Quaranta A, Voza I, Piccoli L, Antonelli A, Marzocchella L, Di Carlo S, Perrotti V, Giganti MG, Piattelli A. *European Journal of Inflammation* Volume 9, Issue 3, Pages 257 - 267 September-December 2011 (IF 0.7/ 5.233) (SJR **Q4**) (cit. 16)
89. [Saposin C mutations in Gaucher disease patients resulting in lysosomal lipid accumulation, saposin C deficiency, but normal prosaposin processing and sorting.](#) Vaccaro AM, Motta M, Tatti M, Scarpa S, **Masuelli L**, Bhat M, Vanier MT, Tylki-Szymanska A, Salvioli R. *Hum Mol Genet*. 2010 Aug 1;19(15):2987-97. doi: 10.1093/hmg/ddq204. Epub 2010 (IF 3.5/ 8.058) (SJR **Q1**) (cit.72)
90. [Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.](#) **Masuelli L**, Marzocchella L, Focaccetti C, Lista F, Nardi A, Scardino A, Mattei M, Turriziani M, Modesti M, Forni G, Schlom J, Modesti A, Bei R. *Cancer Immunol Immunother*. 2010 Aug;59(8):1247-58. doi: 10.1007/s00262-010-0850-0. Epub 2010 Apr 4.PMID: 20364378 (IF 5.8/ 4.263) (SJR **Q1**) (cit.28)
91. [Topical use of sucralfate in epithelial wound healing: clinical evidences and molecular mechanisms of action.](#) **Masuelli L**, Tumino G, Turriziani M, Modesti A, Bei R. *Recent Pat Inflamm Allergy Drug Discov*. 2010 Jan;4(1):25-36. doi: 10.2174/187221310789895649.PMID: 19832693 Review. (SJR **Q1**) (cit.34)
92. [Apoptosis and telomeres shortening related to HIV-1 induced oxidative stress in an astrocytoma cell line.](#) Pollicita M, Muscoli C, Sgura A, Biasin A, Granato T, **Masuelli L**, Mollace V, Tanzarella C, Del Duca C, Rodinò P, Perno CF, Aquaro S. *BMC Neurosci*. 2009 May 22;10:51. doi: 10.1186/1471-2202-10-51.PMID: 19463156 (IF 2.4/ 2.744) (SJR **Q3**) (cit. 16)
93. [Impaired expression and function of signaling pathway enzymes by anthocyanins: Role on cancer prevention and progression](#) Bei R, **Masuelli L**, Turriziani M, Li Volti G, Malaguarnera, M, Galvano F. *Current Enzyme Inhibition* Volume 5, Issue 4, Pages 184 – 197 2009 (SJR **Q4**) (cit. 19)
94. [Evidence of a humoral response to a novel protein WARF4 embedded in the West Nile virus NS4B gene encoded by an alternative open reading frame.](#) Faggioni G, Ciammaruconi A, De Santis R, Pomponi A, Scicluna MT, Barbaro K, **Masuelli L**, Autorino G, Bei R, Lista F. *Int J Mol Med*. 2009 Apr;23(4):509-12. doi: 10.3892/ijmm_00000158.PMID: 19288027 (IF 5.4/ 1.98) (SJR **Q1**) (cit.5)
95. [A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth.](#) Bei R, **Masuelli L**, Palumbo C, Modesti M, Modesti A. *Cancer Lett*. 2009 Aug 18;281(1):8-23. doi: 10.1016/j.canlet.2008.11.009. Epub 2008 Dec 16.PMID: 19091462 Review. (IF 9.7/ 3.741) (SJR **Q1**) (cit.80)

96. [Topical treatment of chronic venous ulcers with sucralfate: a placebo controlled randomized study.](#)
Tumino G, **Masuelli L**, Bei R, Simonelli L, Santoro A, Francipane S. *Int J Mol Med.* 2008 Jul;22(1):17-23.PMID: 18575771 *Clinical Trial.* (IF 5.4/ 1.88) (SJR **Q1**) (cit.23)
97. [Long-lasting tissue inflammatory processes trigger autoimmune responses to extracellular matrix molecules.](#)
Bei R, **Masuelli L**, Palumbo C, Tresoldi I, Scardino A, Modesti A. *Int Rev Immunol.* 2008;27(3):137-75. doi: 10.1080/08830180801939280.PMID: 18437603 *Review.* (IF 5.078) (SJR **Q2**) (cit. 17)
98. [Intercalated disk remodeling in delta-sarcoglycan-deficient hamsters fed with an alpha-linolenic acid-enriched diet.](#)
Masuelli L, Trono P, Marzocchella L, Mrozek MA, Palumbo C, Minieri M, Carotenuto F, Fiaccavento R, Nardi A, Galvano F, Di Nardo P, Modesti A, Bei R. *Int J Mol Med.* 2008 Jan;21(1):41-8.PMID: 18097614 (IF 5.4/ 1.88) (SJR **Q1**) (cit. 10)
99. [Inhibition of nuclear accumulation of phosphorylated ERK by tropomyosin-1-mediated cytoskeletal reorganization](#)
Bharadwaj S, Vasanth G, **Masuelli L**, Thanawala R, Prasad GL. *Journal of Cancer Molecules* Volume 4, Issue 5, Pages 139 – 144 2008 (SJR **Q4**) (cit.6)
100. [The ribosomal P0 protein induces a spontaneous immune response in patients with head and neck advanced stage carcinoma that is not dependent on its overexpression in carcinomas.](#)
Bei R, **Masuelli L**, Trono P, Orvietani PL, Losito S, Marzocchella L, Vitolo D, Albonici L, Mrozek MA, Di Gennaro E, Lista F, Faggioni G, Ionna F, Binaglia L, Manzari V, Budillon A, Modesti A. *Int J Oncol.* 2007 Dec;31(6):1301-8.PMID: 17982655 (IF 5.2/ 2.295) (SJR **Q2**) (cit. 15)
101. [The contribution of peroxynitrite generation in HIV replication in human primary macrophages.](#)
Aquaro S, Muscoli C, Ranazzi A, Pollicita M, Granato T, **Masuelli L**, Modesti A, Perno CF, Mollace V. *Retrovirology.* 2007 Oct 21;4:76. doi: 10.1186/1742-4690-4-76.PMID: 17949509 (IF 3.3/ 4.04) (SJR **Q2**) (cit.28)
102. [Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.](#)
Masuelli L, Focaccetti C, Cereda V, Lista F, Vitolo D, Trono P, Gallo P, Amici A, Monaci P, Mattei M, Modesti M, Forni G, Kraus MH, Muraro R, Modesti A, Bei R. *Int J Oncol.* 2007 Feb;30(2):381-92.PMID: 17203220 (IF 5.2/ 2.295) (SJR **Q2**) (cit.34)
103. [Alpha-linolenic acid-enriched diet prevents myocardial damage and expands longevity in cardiomyopathic hamsters.](#)
Fiaccavento R, Carotenuto F, Minieri M, **Masuelli L**, Vecchini A, Bei R, Modesti A, Binaglia L, Fusco A, Bertoli A, Forte G, Carosella L, Di Nardo P. *Am J Pathol.* 2006 Dec;169(6):1913-24. doi: 10.2353/ajpath.2006.051320.PMID: 17148657 (IF 6/ 5.917) (SJR **Q1**) (cit.43)
104. [Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimotos thyroiditis patients.](#)
Bei R, Mentuccia D, Trono P, **Masuelli L**, Cereda V, Palumbo C, Marzocchella L, Mrozek MA, Pallotta P, Di Lella G, Modesti M, Cerilli M, Frajese GV, Frajese G, Zambruno G, Modesti A. *Int J Immunopathol Pharmacol.* 2006 Jul-Sep;19(3):661-74. doi: 10.1177/039463200601900322.PMID: 17026851 (IF 3.5/3.213) (SJR **Q2**) (cit.21)
105. [Laminin alpha2 chain-positive vessels and epidermal growth factor in lung neuroendocrine carcinoma: a model of a novel cooperative role of laminin-2 and epidermal growth factor in vessel neoplastic invasion and metastasis.](#)
Vitolo D, Ciocci L, Deriu G, Spinelli S, Cortese S, **Masuelli L**, Morrone S, Filice MJ, Coloni GF, Natali PG, Baroni CD. *Am J Pathol.* 2006 Mar;168(3):991-1003. doi:

10.2353/ajpath.2006.041310.PMID: 16507913 (IF 6/ 5.917) (SJR Q1) (cit.11)

106. [Stem cell activation sustains hereditary hypertrophy in hamster cardiomyopathy.](#)

Fiaccavento R, Carotenuto F, Minieri M, Fantini C, Forte G, Carbone A, Carosella L, Bei R, **Masuelli L**, Palumbo C, Modesti A, Prat M, Di Nardo P. *J Pathol.* 2005 Feb;205(3):397-407. doi: 10.1002/path.1717.PMID: 15682436 (IF 7.3/ 6.213) (SJR Q1) (cit.21)

107. [Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.](#)

Bei R, Budillon A, **Masuelli L**, Cereda V, Vitolo D, Di Gennaro E, Ripavecchia V, Palumbo C, Ionna F, Losito S, Modesti A, Kraus MH, Muraro R. *J Pathol.* 2004 Nov;204(3):317-25. doi: 10.1002/path.1642.PMID: 15476268 (IF 7.3/ 5.333) (SJR Q1) (cit.93)

108. [REN\(KCTD11\) is a suppressor of Hedgehog signaling and is deleted in human medulloblastoma.](#)

Di Marcotullio L, Ferretti E, De Smaele E, Argenti B, Mincione C, Zazzeroni F, Gallo R, **Masuelli L**, Napolitano M, Maroder M, Modesti A, Giangaspero F, Screpanti I, Alesse E, Gulino A. *Proc Natl Acad Sci U S A.* 2004 Jul 20;101(29):10833-8. doi: 10.1073/pnas.0400690101. Epub 2004 Jul 12.PMID: 15249678 (IF 10.7/ 10.452) (SJR Q1) (cit. 159)

109. [Beta-catenin accumulates in intercalated disks of hypertrophic cardiomyopathic hearts.](#)

Masuelli L, Bei R, Sacchetti P, Scappaticci I, Francalanci P, Albonici L, Coletti A, Palumbo C, Minieri M, Fiaccavento R, Carotenuto F, Fantini C, Carosella L, Modesti A, Di Nardo P. *Cardiovasc Res.* 2003 Nov 1;60(2):376-87. doi: 10.1016/j.cardiores.2003.08.005.PMID: 14613867 (IF 10.8/ 5.164) (SJR Q1) (cit.69)

110. [Identification of a new missense mutation in the mtDNA of hereditary hypertrophic, but not dilated cardiomyopathic hamsters.](#)

Minieri M, Zingarelli M, Shubeita H, Vecchini A, Binaglia L, Carotenuto F, Fantini C, Fiaccavento R, **Masuelli L**, Coletti A, Simonelli L, Modesti A, Di Nardo P. *Mol Cell Biochem.* 2003 Oct;252(1-2):73-81. doi: 10.1023/a:1025542731335.PMID: 14577578 (IF 4.3/ 1.763) (SJR Q2) (cit.12)

111. [Infection of simian B lymphoblastoid cells with simian immunodeficiency virus is associated with upregulation of CD23 and CD40 cell surface markers.](#)

Titti F, Zamarchi R, Maggiorella MT, Sernicola L, Geraci A, Negri DR, Borsetti A, Menin C, D'Andrea E, Modesti A, **Masuelli L**, Verani P, Chieco-Bianchi L, Amadori A. *J Med Virol.* 2002 Sep;68(1):129-40. doi: 10.1002/jmv.10179.PMID: 12210440 (IF 12.7/ 2.929) (SJR Q1) (cit.6)

112. [The contribution of oxidative stress in apoptosis of human-cultured astroglial cells induced by supernatants of HIV-1-infected macrophages.](#)

Mollace V, Salvemini D, Riley DP, Muscoli C, Iannone M, Granato T, **Masuelli L**, Modesti A, Rotiroti D, Nisticó R, Bertoli A, Perno CF, Aquaro S. *J Leukoc Biol.* 2002 Jan;71(1):65-72.PMID: 11781381 (IF 5.5/ 4.132) (SJR Q1) (cit.48)

113. [Type I consensus IFN \(IFN-con1\) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity in sCID mice.](#)

D'Agostino G, Aricò E, Santodonato L, Venditti M, Sestili P, **Masuelli L**, Coletti A, Modesti A, Picchio G, Mosier DE, Ferrantini M, Belardelli F. *J Interferon Cytokine Res.* 1999 Nov;19(11):1305-16. doi: 10.1089/107999099312984.PMID: 10574624 (IF2.3/ 2.171) (SJR Q2) (cit. 13)

114. [The ras suppressor, RSU-1, enhances nerve growth factor-induced differentiation of PC12 cells and induces p21CIP expression.](#)

Masuelli L, Ettenberg S, Vasaturo F, Vestergaard-Sykes K, Cutler ML. *Cell Growth Differ.* 1999 Aug;10(8):555-64.PMID: 10470855 (IF 1999 3.826) (cit. 13)

115. [Suppression of src-induced transformed phenotype by expression of tropomyosin-1.](#)

Prasad GL, **Masuelli L**, Raj MH, Harindranath N. *Oncogene.* 1999 Mar 18;18(11):2027-31. doi:

10.1038/sj.onc.1202264.PMID: 10208425 (IF 8/ 6.517) (SJR Q1) (cit.55)

116. [Immune responses to all ErbB family receptors detectable in serum of cancer patients.](#)

Bei R, **Masuelli L**, Moriconi E, Visco V, Moretti A, Kraus MH, Muraro R. *Oncogene*. 1999 Feb 11;18(6):1267-75. doi: 10.1038/sj.onc.1202442.PMID: 10022808 (IF 8/ 6.517) (SJR Q1) (cit.66)

117. [The use of a cationic liposome formulation \(DOTAP\) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice.](#)

Bei R, Gupthill V, **Masuelli L**, Kashmiri SV, Muraro R, Frati L, Schlom J, Kantor J. *J Immunother*. 1998 May;21(3):159-69. doi: 10.1097/00002371-199805000-00001.PMID: 9610907 (IF 3.9/ 2.571) (SJR Q1) (cit.36)

118. [Increased expression of the Ras suppressor Rsu-1 enhances Erk-2 activation and inhibits Jun kinase activation.](#)

Masuelli L, Cutler ML. *Mol Cell Biol*. 1996 Oct;16(10):5466-76. doi: 10.1128/MCB.16.10.5466.PMID: 8816460 (IF 5.3/ 10.025) (SJR Q1) (cit.46)

119. [Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.](#)

Abrams SI, Dobrzanski MJ, Wells DT, Stanziale SF, Zaremba S, **Masuelli L**, Kantor JA, Schlom J. *Eur J Immunol*. 1995 Sep;25(9):2588-97. doi: 10.1002/eji.1830250928.PMID: 7589131 (IF 5.4/ 5.256) (SJR Q1) (cit.40)

120. [The Ras suppressor RSU-1 localizes to 10p13 and its expression in the U251 glioblastoma cell line correlates with a decrease in growth rate and tumorigenic potential.](#)

Tsuda T, Marinetti MR, **Masuelli L**, Cutler ML. *Oncogene*. 1995 Jul 20;11(2):397-403.PMID: 7624154 (IF 8/ 6.517) (SJR Q1) (cit.37)

121. [Ultrastructural evidence of the mechanisms responsible for interleukin-4-activated rejection of a spontaneous murine adenocarcinoma.](#)

Modesti A, **Masuelli L**, Modica A, D'Orazi G, Scarpa S, Bosco MC, Forni G. *Int J Cancer*. 1993 Apr 1;53(6):988-93. doi: 10.1002/ijc.2910530622.PMID: 8473057 (IF 6.4/ 3.362) (SJR Q1) (cit.38)

122. [Selective transformation of host lymphocytes in vivo by retrovirus-producing macrophages.](#)

Bosco MC, Musso T, Gusella GL, Giovarelli M, Forni M, Soleti A, **Masuelli L**, Modesti A, Forni G, Varesio L. *J Immunol*. 1993 Jan 1;150(1):278-89.PMID: 8417128 (IF 4.4/ 6.937) (SJR Q1) (cit.3)

123. [Modulation of laminin synthesis in human neuroblastoma cells during retinoic acid induced differentiation.](#)

Scarpa S, D'Orazi G, Ragano-Caracciolo M, Cardelli P, **Masuelli L**, Modesti A. *Cancer Lett*. 1992 May 30;64(1):31-7. doi: 10.1016/0304-3835(92)90018-q.PMID: 1596874 (IF 9.7/ 1.44) (SJR Q1) (cit.6)

124. [Human immunodeficiency virus \(HIV\)-infected tumor xenografts as an in vivo model for antiviral therapy: role of alpha/beta interferon in restriction of tumor growth in nude mice injected with HIV-infected U937 tumor cells.](#)

Puddu P, Locardi C, Sestili P, Varano F, Petrini C, Modesti A, **Masuelli L**, Gresser I, Belardelli F. *J Virol*. 1991 May;65(5):2245-53. doi: 10.1128/JVI.65.5.2245-2253.1991.PMID: 1901915 (IF 5.4/ 5.821) (SJR Q1) (cit.12)

125. [Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.](#)

Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, **Masuelli L**, Forni G. *J Immunol*. 1990 Nov 1;145(9):3136-43.PMID: 2212677 (IF 4.4/ 6.937) (SJR Q1) (cit.96)

Presentations at conferences Over 50 congress presentations on cancer biology, immunotherapy and radioprotection, 4 oral presentations

Book chapter Bei R, **Masuelli L**, Palumbo C, Modesti A: Autoantibodies to extracellular matrix component as outcome of tissue chronic inflammation. In “Autoantibodies Research Progress” (2008) Ed. Quentin P. Dubois, NOVA Publisher, Capitolo 3, pp 99-125

Monograph BEI R, **MASUELLI L**, TUMINO G, GROSSO E. L'utilizzo topico del sucralfato nel processo di guarigione delle ferite. (2010) CRITICAL MEDICINE REVIEW, Critical Medicine Publishing srl

| Key words | Brief description |
|---|--|
| Novel Biomarkers Extracellular vesicles | In the last few years, Prof. Masuelli has been involved in the morpho-molecular and immunological characterization of microvesicles and exosomes as novel biomarkers in <i>in vitro</i> experimental preclinical models and in patients' liquid biopsies (cancer patients and cerebrovascular patients). Moreover, she is involved in the characterization of novel biomarkers in <i>in vitro</i> preclinical models (cell cultures, <i>in vivo</i> experimental models) and in samples from patients (tissues, primary cell cultures, liquid biopsies) 2. J. Endocrinol Invest. 2023 Jun 7. doi: 10.1007/s40618-023-02115-2; 3. Int J Mol Sci. 2023 May 30;24(11):9467. doi: 10.3390/ijms24119467; 7. Int J Mol Sci. 2023 Apr 6;24(7):6862. doi: 10.3390/ijms24076862; 13. J Transl Med. 2022 Oct 15;20(1):469. doi: 10.1186/s12967-022-03668-1; 15. Sci Rep. 2022 Aug 25;12(1):14483. doi: 10.1038/s41598-022-18719-2; 18. Cancers (Basel). 2022 May 14;14(10):2435. doi: 10.3390/cancers14102435; 20. J Extracell Vesicles. 2022 Jan;11(1):e12176. doi: 10.1002/jev2.12176; 47. Cancer Immunol Res. 2018 Jul;6(7):860-869. doi: 10.1158/2326-6066.CIR-17-0604; 53. Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372 Collaborations: Department of Molecular Medicine, University of Rome Sapienza, Policlinico Campus Biomedico Rome, EBRI Milan |
| Multiomic transition | In the last few years, Prof. Masuelli has been involved in the integration of data deriving from multiomic profiling, such as genomic and proteomic data of preclinical cancer models and human samples (tissues, primary cell cultures, liquid biopsies) from cancer patients. 1. Biomedicines. 2023 Jun 19;11(6):1761. doi: 10.3390/biomedicines11061761 13. J Transl Med. 2022 Oct 15;20(1):469. doi: 10.1186/s12967-022-03668-1 16. J Transl Med. 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9. 17. Brain. 2022 Aug 27;145(8):2687-2703. doi: 10.1093/brain/awac145 |
| Cancer Target Therapy Preclinical models | Prof. Masuelli has a long experience on the analysis of the <i>in vitro</i> and <i>in vivo</i> biological effects of drugs for target therapy, used alone or in combination, employing preclinical models for anti-cancer therapy. These drugs include inhibitors of growth factor receptors and cytoplasmic signaling molecules. 5. Biol Direct. 2023 Apr 17;18(1):17. doi: 10.1186/s13062-023-00374-w; 16. J Transl Med. 2022 Jun 25;20(1):286. doi: 10.1186/s12967-022-03490-9 25. Sci Rep. 2021 Sep 24;11(1):19051. doi: 10.1038/s41598-021-98450-6 38. Invest New Drugs. 2020 Jun;38(3):675-689. doi: 10.1007/s10637-019-00827-y 44. Front Pharmacol. 2018 Nov 6;9:1269. doi: 10.3389/fphar.2018.01269 61. Oncotarget. 2016 Feb 23;7(8):9250-70. doi: 10.18632/oncotarget.7062 62. Tumour Biol. 2016 Mar;37(3):3705-17. doi: 10.1007/s13277-015-4207-3 64. Hum Mol Genet. 2015 Dec 15;24(24):6921-31. doi: 10.1093/hmg/ddv39 66. J Transl Med. 2015 Mar 28;13:101. doi: 10.1186/s12967-015-0455-7 Collaborations: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata |
| Nutraceuticals Preclinical models | Prof. Masuelli has a long experience on the analysis of the <i>in vitro</i> and <i>in vivo</i> biological effects of nutraceuticals, used alone or in combination, employing preclinical models for anti-cancer treatment and prevention, and for cardiomyopathies. 24. Pharmaceuticals (Basel). 2021 Oct 22;14(11):1068. doi: 10.3390/ph14111068 31. Pharmacol Ther. 2021 Mar;219:107700. doi: 10.1016/j.pharmthera.2020.107700 35. Nutrients. 2020 May 14;12(5):1417. doi: 10.3390/nu12051417 |

| | |
|---|--|
| | <p>44. Front Pharmacol. 2018 Nov 6;9:1269. doi: 10.3389/fphar.2018.01269</p> <p>50. Oncoimmunology. 2017 Jul 31;6(11):e1356151. doi: 10.1080/2162402X.2017.1356151</p> <p>51. Front Pharmacol. 2017 Jun 19;8:373. doi: 10.3389/fphar.2017.00373</p> <p>55. Oncotarget. 2017 May 23;8(21):34405-34422. doi: 10.18632/oncotarget</p> <p>56. Int J Food Sci Nutr. 2017 May;68(3):298-312. doi: 10.1080/09637486.2016.1236077</p> <p>67. Oncotarget. 2014 Nov 15;5(21):10745-62. doi: 10.18632/oncotarget.2534</p> <p>74. J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):105-19</p> <p>81. Front Biosci (Landmark Ed). 2012 Jan 1;17(2):498-508. doi: 10.2741/3940</p> <p>85. Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1833-43. doi: 10.2741/3825</p> <p>86. Front Biosci (Landmark Ed). 2011 Jan 1;16(3):1060-8. doi: 10.2741/3735</p> <p>98. Int J Mol Med. 2008 Jan;21(1):41-8</p> <p>103. Am J Pathol. 2006 Dec;169(6):1913-24</p> <p>109. Cardiovasc Res. 2003 Nov 1;60(2):376-87. doi: 10.1016/j.cardiores.2003.08.00</p> <p>Collaborations: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata</p> |
| <p>Cancer immunotherapy</p> <p>Preclinical models</p> | <p>Prof. Masuelli has a long experience on the study of cancer immunology including the development of anti-cancer vaccines using preclinical models.</p> <p>35. Nutrients (MDPI) 2020 May 14;12(5):1417. doi: 10.3390/nu12051417</p> <p>69. J Transl Med. 2014 May 10;12:122. doi: 10.1186/1479-5876-12-122</p> <p>75. Oncol Rep. 2013 Mar;29(3):1167-74. doi: 10.3892/or.2012.2197</p> <p>87. Cancer Sci. 2011 Mar;102(3):509-15. doi: 10.1111/j.1349-7006.2010.01814.x</p> <p>90. Cancer Immunol Immunother. 2010 Aug;59(8):1247-58. doi: 10.1007/s00262-010-0850-0</p> <p>100. Int J Oncol. 2007 Dec;31(6):1301-8.</p> <p>102. Int J Oncol. 2007 Feb;30(2):381-92</p> <p>107. J Pathol. 2004 Nov;204(3):317-25.</p> <p>116. Oncogene. 1999 Feb 11;18(6):1267-75. doi: 10.1038/sj.onc.1202442</p> <p>117. J Immunother. 1998 May;21(3):159-69. doi: 10.1097/00002371-199805000-00001</p> <p>119. Eur J Immunol. 1995 Sep;25(9):2588-97. doi: 10.1002/eji.1830250928</p> <p>121. Int J Cancer. 1993 Apr 1;53(6):988-93. doi: 10.1002/ijc.2910530622</p> <p>125. J Immunol. 1990 Nov 1;145(9):3136-43</p> <p>Collaborations: Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata</p> |
| Human Ultrastructural Pathology | <p>Prof. Laura Masuelli is employed as Dirigente Medico I livello at the Azienda Ospedaliera Universitaria Policlinico Umberto I where she is involved in ultrastructural diagnosis of human diseases (including kidney pathology, lysosomal storage diseases, pulmonary pathologies, amyloidosis) using transmission electron microscopy on human biopsies. Moreover, she performs ultrastructural characterization of primary cell cultures derived from patients affected by neurological disorders or lysosomal storage diseases.</p> <p>17. Brain. 2022 Aug 27;145(8):2687-2703. doi: 10.1093/brain/awac145</p> <p>21. Hum Mutat. 2022 Jan;43(1):67-73. doi: 10.1002/humu.24293</p> <p>22. Brain. 2022 Mar 29;145(1):208-223. doi: 10.1093/brain/awab299</p> <p>23. Am J Obstet Gynecol MFM. 2022 Jan;4(1):100523. doi: 10.1016/j.ajogmf.2021.100523</p> <p>41. Mol Genet Metab Rep. 2019 Aug 21;21:100502. doi: 10.1016/j.ymgmr.2019.100502</p> <p>89. Hum Mol Genet. 2010 Aug 1;19(15):2987-97. doi: 10.1093/hmg/ddq204</p> <p>Collaborations: Meyer Hospital Florence, Institute of Child Neuropsychiatry Sapienza University of Rome, DAI Maternal and Child Policlinico Umberto I, Rome</p> |
| Nanocarriers | <p>In the last few years, Prof. Masuelli has been involved in the characterization of nanosystems for the delivery of nucleic acids, drugs and nutraceuticals for anti-cancer therapy.</p> <p>4. Carbohydr Polym. 2023 Aug 15;314:120900. doi: 10.1016/j.carbpol.2023.120900</p> <p>12. Appl Mater Interfaces. 2022 Dec 28;14(51):56666-56677. doi: 10.1021/acsami.2c20019</p> <p>14. Pharmaceutics. 2022 Aug 15;14(8):1698. doi: 10.3390/pharmaceutics14081698</p> <p>19. ACS Nano. 2022 Feb 22;16(2):2088-2100. doi: 10.1021/acsnano.1c07687</p> <p>27. Pharmaceutics. 2021 Aug 19;13(8):1292. doi: 10.3390/pharmaceutics13081292</p> <p>42. Nat Commun. 2019 Aug 15;10(1):3686. doi: 10.1038/s41467-019-11642-7</p> <p>Collaborations: Department of Molecular Medicine, Sapienza University of Rome, Department of Pharmaceutical Chemistry and Technology, Sapienza University of Rome</p> |
| Cancer signal transduction | <p>Prof. Laura Masuelli has been also involved in the characterization of different signal transduction pathways altered during carcinogenesis, including growth factor receptors, transducers, small G proteins in preclinical models, including manipulation of in vitro and in vivo experimental models.</p> <p>9. Cancers (Basel). 2023 Feb 25;15(5):1471. doi: 10.3390/cancers1505147180.</p> <p>80. J Cell Physiol. 2012 Sep;227(9):3344-53. doi: 10.1002/jcp.24034.PMID: 22213373</p> <p>108. Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8. doi: 10.1073/pnas.0400690101</p> <p>114. Cell Growth Differ. 1999 Aug;10(8):555-64</p> |

| |
|--|
| 115. Oncogene. 1999 Mar 18;18(11):2027-31. doi: 10.1038/sj.onc.1202264 118. Mol Cell Biol. 1996 Oct;16(10):5466-76. doi: 10.1128/MCB.16.10.5466 120. Oncogene. 1995 Jul 20;11(2):397-403 |
|--|

Teaching activities

- 2023/2024** **Patologia e Fisiopatologia Generale, CLM B Medicina e Chirurgia**, Università di Roma "Sapienza", **ssd MED/04, 2CFU**
- 2000-to date** **Patologia e Fisiopatologia Generale, CLM A Medicina e Chirurgia**, Università di Roma "Sapienza", **ssd MED/04, 2CFU**
- Attività didattica Elettiva di Patologia Generale, CLM A Medicina e Chirurgia**, Università di Roma "Sapienza", **ssd MED/04, 1 CFU**
- 2010-to date** **Basi fisiopatologiche delle malattie, CL Fisioterapia A**, Università di Roma "Sapienza", **ssd MED/04-05 2 CFU, MED/08 1CFU, Coordinatore CI**
- 2018-to date** **Metodologie diagnostiche di anatomia patologiche, CL Tecniche di laboratorio biomedico**, modulo di **Tecniche ultrastrutturali**, Università di Roma "Sapienza"-AO San Camillo-Forlanini, **ssd MED/46, 1CFU**
- Metodologie diagnostiche di anatomia patologiche, CL Tecniche di laboratorio biomedico**, modulo di **Tecniche ultrastrutturali**, Sabina Universitas Rieti, **ssd MED/46, 1CFU**
- Tecnologie avanzate nella diagnostica di laboratorio, CL Tecniche di laboratorio biomedico**, Sabina Universitas Rieti, **ssd MED/46, 1CFU, Coordinatore CI**
- 1999-to date** **Patologia Generale, Scuola di Specializzazione in Patologia clinica e Biochimica clinica** Università di Roma "Sapienza", **ssd MED/04**
- 2010-2013** **Patologia generale, CI Patologia generale e Microbiologia, CL Terapia Occupazionale**, sede Viterbo-Montefiascone, Università di Roma "Sapienza", **ssd MED/04, 3CFU, Coordinatore CI**
- 2001-2010** **Patologia generale, CI Patologia generale e Microbiologia, CL Fisioterapia A**, sede Policlinico Umberto I, Università di Roma "Sapienza", **ssd MED/04, 3CFU, Coordinatore CI**
- 2001-2009** **Patologia clinica, CI Patologia clinica e diagnostica per immagini, CL Fisioterapia A**, sede Policlinico Umberto I, Università di Roma "Sapienza", **ssd MED/05, 2CFU, Coordinatore CI**
- 1998-2001** **ADI Patologia Generale, CL Fisioterapia A**, sede Policlinico Umberto I, Università di Roma "Sapienza", **ssd MED/04, 2CFU**

Memberships and managerial activity

Section Editorial Board, Biochemistry section, "International Journal of Molecular Sciences", IF 5.6

Guest editor for Special issues in "Nutrients" (IF 5.9) (2019- Flavonoids and Cancer Prevention), in "International Journal of Molecular Sciences" (IF 5.6) (2023- Extracellular Vesicles in Cancer Prevention and Treatment; 2022- Novel Therapeutic Targets for Tumor Microenvironment in Cancer)

La sottoscritta, consapevole che le dichiarazioni false comportano l'applicazione delle sanzioni penali previste dall'art. 76 del D.P.R. 445/2000, dichiara che le informazioni riportate nel seguente curriculum vitae, redatto in formato europeo, corrispondono a verità. Inoltre, la sottoscritta autorizza al trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003 per le finalità di cui al presente avviso di candidatura e dichiara di essere esente da conflitti di interessi ai sensi del D.Lgs 39/2013.

Roma, 24 luglio 2023